CAV1 in prostate cancer could induce epithelial–mesenchymal transition through activating cancer immune evasion, and CAV1 in cancer-derived exosomes was able to induce chemoresistance in recipient cells (Lin et al., 2019), which conformed to our results revealed in GEM-resistant BCa. This evidence concerns the gene CAV1 and prostate carcinoma.